Biomea Fusion, Inc.
NNASDAQ:BMEACapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Michael J. M. Hitchcock
- Full Time Employees
- 41
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- 1599 Industrial Road San Carlos CA United States 94070
- IPO Date
- Apr 16, 2021
- CIK
- 0001840439
- Website
- biomeafusion.com
- Similar Companies
- Business
- Biomea Fusion, Inc. (BMEA) is a clinical-stage biopharmaceutical company that develops oral covalent small-molecule inhibitors targeting genetically defined cancers and metabolic diseases, including diabetes and obesity, using its proprietary FUSION System discovery platform. The company offers a pipeline of novel candidates, including icovamenib (BMF-219), an oral menin inhibitor in Phase II trials for type 2 diabetes (T2D; COVALENT-111 with positive 52-week data and COVALENT-112 ongoing), type 1 diabetes (T1D), and previously in oncology indications such as acute myeloid leukemia and multiple myeloma; BMF-650, a next-generation oral GLP-1 receptor agonist in Phase I (GLP-131) for obesity with preclinical nonhuman primate data showing up to 15% weight loss; and earlier-stage assets like BMF-500 (FLT3 inhibitor). Founded in 2017 and headquartered in Redwood City, California, Biomea Fusion operates primarily in the United States with global preclinical and clinical activities focused on patients underserved by existing therapies. Recent developments include a strategic realignment to prioritize diabetes and obesity programs by discontinuing certain oncology efforts, a June 2025 public offering raising approximately $42.8 million to extend cash runway into second-half 2026, workforce and expense reductions targeting 40% quarterly cuts, Investigational New Drug submission and first-patient dosing for BMF-650 in 2025, planned Phase II initiations for icovamenib in severe insulin-deficient T2D (COVALENT-212) and GLP-1 inadequate responders (VALE-212) in Q4 2025, and an oral presentation on icovamenib at the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease in December 2025.
Company News
Biomea Fusion’s BMF-650 Shows Up to 6.1% Weight Loss in Early GLP-1 Study
Biomea Fusion's BMF-650 Shows Up to 6.1% Weight Loss in Early GLP-1 Study
Biomea Fusion, Inc. (BMEA) Discusses BMF-650 Phase I Topline Results and Potential for Separating GI Side Effects from Weight Loss Transcript
Biomea Fusion Announces Phase 1 Results for BMF-650, its Investigational Next-Generation Oral Small Molecule GLP-1 Receptor Agonist
Biomea Fusion to Announce Phase I Results for BMF-650, Its Next-Generation Oral Small-Molecule GLP-1 Receptor Agonist
Bearish Sentiment: Biomea Fusion Scraps Equity Offering, Delays Study Data
Biomea Fusion Announces Termination of Proposed Public Offering of Securities
Biomea Fusion Announces Proposed Public Offering of Securities
After Golden Cross, Biomea Fusion, Inc. (BMEA)'s Technical Outlook is Bright
Biomea Fusion to Participate in Upcoming Investor Conferences
Biomea Fusion Stock Surges on Phase II Diabetes Trial Enrollment Completion
Biomea Fusion Announces Completion of Enrollment in COVALENT-211 Phase II Trial of Icovamenib in Insulin-Deficient Type 2 Diabetes
Citi sees up to 410% upside in 2 biotech stocks: is the risk worth it?
Biomea Fusion Announces First Patient Dosed in OPAL Study Evaluating Icovamenib in Combination with Semaglutide in Obesity
Biomea Fusion Reports Second Quarter 2026 Financial Results and Corporate Highlights
Biomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association (“ADA”) 86th Scientific Sessions and Announces Expansion of Ongoing Phase I BMF-650 Study
Biomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association (“ADA”) 86th Scientific Sessions and Announces Expansion of Ongoing Phase I BMF-650 Study
Biomea Fusion Announces Research Collaboration with University of Leicester to Evaluate Icovamenib in Combination with Semaglutide in Obesity
Biomea Fusion to Participate at Upcoming Investor Conferences
Biomea Fusion Reports First Quarter 2026 Financial Results and Corporate Highlights